7 Highlights from Raffles Medical Group Ltd’s Q1 2019 Earnings
- Original Post from The Motley Fool Sg

Earlier this morning, Raffles Medical Group Ltd (SGX: BSL), or RMG for short, released its first quarter fiscal year 2019 (Q1 2019) earnings report. As a quick recap, RMG runs hospital and healthcare services in both Singapore and China, and has a network of clinics in both Singapore and four other Asian countries. In China, it has completed the construction of one hospital while another is under development.


Here are seven highlights from RMG’s latest earnings report:



  1. Revenue for Q1 2019 rose by 6.7% year-on-year to S$128.3 million from S$120.2 million a year ago. Revenue from healthcare services and hospital services divisions grew by 8.9% and 3.2%, respectively. For healthcare services, higher revenue was recorded due to an increase in premium from existing and new clients as well as the Primary Care Network (PCN) scheme and other projects. Hospital services saw better revenue contribution due to higher utilisation of hospital facilities.

  2. Due to higher start-up costs for Raffles Hospital Chongqing (RCQ), operating profit for RMG declined by 9.4% year-on-year to S$17.1 million. As a result, net profit after tax declined by 13.7% year-on-year to S$13.6 million. If the results of RCQ are excluded from the group, net profit after tax would have grown by 2.1% year-on-year. The company said that the gestation loss for RCQ is within expectation.

  3. RMG’s balance sheet remains strong with S$111.8 million of cash and S$126 million of debt. The group continues to generate healthy operating cash flows of S$21.7 million, while capital expenditure was elevated during the quarter at S$26.4 million due to the construction of Raffles Hospital Pudong in Shanghai, China.

  4. Raffles Hospital Singapore officially opened its new block Raffles Specialist Centre in March 2019. The complex is equipped with ambulatory and inpatient services from 31 different specialties, and would enable the group to provide quality care and services to customers.

  5. Another eight clinics were added to Raffles Medical clinics’ PCN of 40 clinics to enhance convenience to more patients and to branch out to more areas in Singapore for easier access to patients.

  6. The directors expect RMG to be able to grow its revenue and remain profitable for 2019, notwithstanding the expected gestation loss for RCQ.

  7. RMG’s trailing 12-months earnings per share stands at 3.84 Singapore cents. Based on the closing price for RMG of S$1.07 as of 26 April 2019, the group is trading at a trailing 12-months price earnings ratio of 27.9x. With a full-year trailing dividend of 2.5 Singapore cents, historical dividend yield stands at 2.3%.


All seems to be in order to at RMG, as the expected gestation loss for RCQ is within expectations. The group continues to demonstrate resilience in its core operations, with both divisions showing growth. With the opening of Raffles Specialist Centre and the addition of clinics to the PCN, both divisions should continue to witness healthy growth.


Raffles Health Connect’s platform, which was launched just three months ago in January 2019, should continue to see slow and steady uptake. Investors should maintain a long-term view with regards to RMG’s China expansion as it is still early days for the group, as it is anticipated that each hospital would need at least three to four years to break even.


There are 28 surprising and important things we think every Singaporean investor should know—and we’ve laid them all out in The Motley Fool Singapore’s new e-book. Packed with information and insights, we believe this book will help you be a better, smarter investor. You can download the full e-book FREE of charge—simply click here now to claim your copy.


More reading



The information provided is for general information purposes only and is not intended to be personalized investment or financial advice. The Motley Fool Singapore has a recommendation for Raffles Medical Group Ltd. The Motley Fool Singapore contributor Royston Yang owns shares in Raffles Medical Group Ltd.


$Raffles Medical(BSL.SI)

Read more
1 like

Recommended & Related Posts

Raffles Medical Group Ltd: Key Risks and When I’ll Sell
- Original Post from The Motley Fool Sg


Despite its poor share price performance over the last few years, Raffles Medical Group Ltd (SGX: BSL) remains a key part of my portfolio. Its long-term growth potential in China coupled with its strong core business and relatively low valuation make me believe the healthcare operator will be a great long-term winner.


However, despite my optimism, there are risks to the investment. Here are two that could potentially derail its growth — and what it would take for me to consider selling.


No. 1: Stumbling block in China


With the opening of two new hospitals in China, the middle kingdom could be the next avenue of growth for Raffles Medical. However, expansion into China comes with unique challenges.


If the company is unable to attract patients to its hospitals, the road to profitability may take longer than expected.


Withits expansion into China, Raffles Medical will also be exposed to currency and regulatory risk.


No. 2: Cash flow issues


Raffles Medical has spent a sizeable amount of money to open the two hospitals in China. It now has a net debt of S$23 million. The company again burned cash in the second quarter of 2019 in preparation for the opening of its hospital in Shanghai.


Although its balance sheet still remains relatively robust, an unexpected extended period of cash burn may weaken the healthcare operator’s balance sheet.


Scenarios in which I might sell


For now, Raffles Medical remains a key part of my portfolio, and I intend to keep it that way. My investment thesis revolves around its strong core business in Singapore, huge growth potential in China, and a prudent management team. However, this could change in the future.


Alarm bells will ring if growth in China runs into obstacles and the company is unable to turn its China operations profitable over the next five years, On top of that, I will be keeping an eye on the company’s cash burn rate in regards to its operation in China. Currently, the company remains in a robust financial position. But if its balance sheet weakens considerably and it continues to burn cash in China with no end in sight, I may have to reconsider my position.


More reading



The information provided is for general information purposes only and is not intended to be personalized investment or financial advice. The Motley Fool Singapore has recommended shares of Raffles Medical Group Ltd. Motley Fool Singapore contributor Jeremy Chia owns shares in Raffles Medical Group Ltd.


$Raffles Medical(BSL.SI)

Read more
Here’s How Much You Would Have Made If You Had Invested S$1,000 in Raffles Medical Group 20 Years Ago
- Original Post from The Motley Fool Sg


Over the last five years, Raffles Medical Group Ltd (SGX: BSL) shares have tumbled 28% and now trade close to a five-year low.However, that is not to say that the healthcare giant has not been a massive winner over the longer term. Since it was listed in Singapore in 2000, the healthcare provider has grown at a breakneck pace, becoming one of Singapore’s most recognisable healthcare brands.


Looking back


I took a trip down memory lane to see how much an investor would have made if they had invested in Raffles Medical around 20 years ago.


In 2000, shares of Raffles Medical traded at a split-adjusted price of 23.5 Singapore cents per share. Today, Raffles Medical shares exchange hands for around 96.5 Singapore cents. That equates to a 310.6% gain in that time frame. For perspective, $1,000 invested at that time would now be worth S$4,106.


Doing the math, that translates to a decent annualised growth of 7.3%. On top of that, Raffles Medical has been a regular payer of dividends. Last year, Raffles Medical paid out a dividend of 2.5 Singapore cents per share. Based on an initial outlay of 23.5 Singapore cents per share in 2000, that would translate into a juicy 10.6% annual yield on the initial investment.


Not a smooth ride


However, the returns of the stock were by no means smooth. From 2000 to 2008, its shares rose by almost 100%. Unfortunately, the great financial crisis of 2008 scared off many investors who began selling down the stock, which soon returned to its 2000 level.


But Raffles Medical in 2009 was in a much better position than it was in 2000. Its 2009 revenue was three times more than it was in 2000, while its profit was more than seven times higher.


Unsurprisingly, the dip in its share price then was short-lived. Its shares soon started regaining all that it had lost in 2008 and more.


Lessons learnt


There are a few lessons that can be learnt from Raffles Medical’s twenty-year history.



  1. Never underestimate the power of long-term investing. Despite the volatility, investors who were patient enough to hold on to its shares for the whole 20 years have been well-rewarded.

  2. Do not panic during a broad market sell-off. As seen in 2008, even fundamentally sound companies suffered major sell-downs. As investors, it is easy to panic and push the sell button at the first sign of trouble. However, investors who did sell would have not enjoyed the massive gains that Raffles Medical has afforded loyal shareholders.


Today, Raffles Medical shares have again suffered a massive sell-down. It currently trades at around 30.6 times its annualised earnings. At a glance, this may not seem excessively cheap. However, there are a few things to note.


First, Raffles Medical Group earnings have been dragged down due to near-term teething losses from the opening of its first hospital in China. Second, despite the risks involved, the new China hospitals could potentially be a huge driver of profits over the longer term. Co-founder and chairman, Dr. Loo Choon Yong, is hopeful that China will contribute more than 50% of the group’s revenue in the future.


As such, its shares could see a massive boost once its China hospitals start turning profitable. If the past is anything to go by and considering the healthcare provider’s massive potential in China, I think it is likely that patient investors who pick up shares today will be well-rewarded in the next 20 years.


Want to read about another Singapore stock we love? Read about one of our stock picks that has shot up 78% in just 2 years. We reveal the amazing story behind this stock …and how you can potentially profit from it. Click here to download the free report now.


More reading



The information provided is for general information purposes only and is not intended to be personalized investment or financial advice. The Motley Fool Singapore has recommended shares of Raffles Medical Group Ltd. Motley Fool Singapore contributor Jeremy Chia owns shares in Raffles Medical Group Ltd.


$Raffles Medical(BSL.SI)

Read more
Raffles Medical Group Ltd’s Share Price Plunged 20% in 2019. Here’s Why.
- Original Post from The Motley Fool Sg


Raffles Medical Group Ltd (SGX: BSL) runs hospital and healthcare services in Singapore. It also has a network of clinics in five countries and thirteen cities. Furthermore, it has two hospitals (one under development) in China.


Year-to-date, Raffles Medical’s share price declined by 20% from its peak of S$1.20. Here, let’s try to understand what might have caused the decline.


The culprit


There are many reasons that cause the stock price of a company to move. Generally, stock price movement is driven either by business performance or investor sentiments.


The former is related to how a business performs in a given period, looking at metrics like growth, margins, production and others. Here, the ultimate driver is profit. The latter is driven more by investors’ overall mood, which is described by emotional pairs such as greed and fear, optimistic and pessimistic, bull and bear, etc.


In this case of Raffles Medical, I believe both factors contribute to the recent decline in its share price.


Let’s start with the some numbers.


In the first half of 2019, Raffles Medical reported that revenue was up by 6.2% year-on-year to S$255.3 million. Yet, profit for the period fell by 13.5% to S$27.9 million. The decline in profit was driven mainly by gestation losses by Raffles Hospital Chongqing.


Clearly, the decline in net profit has impacted the company’s share price. On a positive note, Raffles Medical continued to grow its top-line.


Overall, I feel it’s not all that bad.


Nevertheless, the market clearly expected more from the company. This might explain the 20% decline in the healthcare provider’s share price (which is more than the 13.5% decline in net profit for the period).


Looking ahead


Going forward, Raffles Medical needs to prove that it can ramp up the operation of its hospitals in China to improve its bottom-line. Moreover, it will also need to control its cost to improve its profitability.Failure to improve its profitability will likely put its share price in the firing line again.


Want to keep up to date with how market volatility can impact the investment landscape here in Singapore? Click here now for your FREE subscription to The Motley Fool’s investing newsletter. ‘Take Stock’ lets you know exactly what’s happening in today’s markets, and shows how you can protect your wealth in the years ahead by clicking here


More reading



The information provided is for general information purposes only and is not intended to be personalised investment or financial advice. Motley Fool Singapore contributor Lawrence Nga doesn’t own shares in any companies mentioned. The Motley Fool Singapore has recommended the shares of Raffles Medical Group Ltd.


$Raffles Medical(BSL.SI)

Read more
Better Buy: Raffles Medical Group Ltd vs. IHH Healthcare Bhd
- Original Post from The Motley Fool Sg


Raffles Medical Group Ltd (SGX: BSL) and IHH Healthcare Bhd (SGX: Q0F) are two of the largest healthcare companies listed in Singapore. Both companies operate hospitals and medical centres around the region.


In the last five years, IHH Healthcare’s stock has declined 3.6%, while Raffles Medical’s shares have plunged 26.5%. While the pair of healthcare companies have not fared so well in the past, the future may sing a different tune, with both companies making big strides by opening new hospitals in China.


With that said, here’s a quick comparison to find out which of the two companies makes a better investment today.


Introducing the contenders


On the surface, Raffles Medical Group Ltd and IHH Healthcare Bhd have fairly similar businesses. But there are actually important differences to appreciate.


Raffles Medical Group owns a network of medical clinics and a hospital in Singapore. It also has an investment property in Holland Village that contributes rental income. The group recently expanded overseas by acquiring a network of clinics in China and also opened a joint venture hospital in Chongqing, China. A second hospital in China is expected to be opened later this year.


IHH Healthcare Bhd is a much larger company than Raffles Medical. It operates 84 hospitals around the world, including well-known brands such as Gleneagles and Parkway in Singapore. It also has a 35.69% stake in Parkway Life REIT.


The group is opening a Gleneagles in Chengdu and Shanghai over the next few quarters and acquired a 31.17% stake in Fortis Healthcare last year, expanding its footprint in India.


Growth prospects


Both Raffles and IHH have decent growth prospects.


Raffles Medical Group opened its first hospital in China late last year and will be opening a second hospital there later this year. While these two new hospitals are expected to incur gestational losses at the start, they will hopefully eventually become profitable and start being accretive to earnings.


IHH Healthcare has also laid the foundations for future growth.The group’s Gleneagles Hong Kong hospital was set up in 2017 and is still undergoing stabilisation. And as mentioned earlier, IHH is also opening two new hospitals in Chengdu and Shanghai, which are expected to be open in the fourth quarter of 2019 and the second half of 2020 respectively. On top of that, 2019 is the first year that the newly-acquired stake in Fortis will contribute to its bottom line.


However, because of IHH’s relatively larger size, it will take much more to move the needle for the company. As such, I believe Raffles’ two new hospitals in China will make a bigger impact on its bottom line than what IHH has in its pipeline.


Winner: Raffles Medical Group


Financial strength


Beyond their runway for growth, another important aspect to compare is the pair’s financial muscle and cash reserves. A larger cash reserve means that a company will not need to dip into debt markets that can increase its financing costs.


Raffles Medical does considerably better in this respect. It has a net-debt-to-equity ratio of just 0.03 times.


On the other hand, IHH Healthcare has a net-debt-to-equity ratio of 0.15 times.


Winner: Raffles Medical Group


Valuation


Lastly, from a valuation standpoint, Raffles Medical seems to come out on top again. Based on 2019 first-half results, Raffles Medical has a price-to-annualised earnings of around 31 times, while IHH shares trade at around 66 times its annualised earnings.


Raffles Medical also trades at a price-to-book ratio of 2.16 compared to IHH healthcare which trades at a price-to-book of around 2.27 (after excluding perpetuities and non-controlling interests).


On both counts, Raffles Medical Group looks to be the cheaper option.


Winner: Raffles Medical Group


The Foolish conclusion


All things considered, Raffles Medical Group seems to be the better buy for now. Not only does it have better growth prospects in terms of its size, but Raffles also has a lower net-debt-to-equity ratio and its shares trade at a discount to IHH shares.


Want to know one Singapore stock that’s set to keep growing its dividends and deliver growth? We reveal our FREE stock report for all our readers and why we think it will reward investors. Click here now to download the report now.


More reading



The information provided is for general information purposes only and is not intended to be personalized investment or financial advice. The Motley Fool Singapore has recommended shares of Raffles Medical Group Ltd. Motley Fool Singapore contributor Jeremy Chia owns shares in Raffles Medical Group Ltd.


$Raffles Medical(BSL.SI)

Read more
Best Healthcare Stock: Raffles Medical Group Ltd or Singapore O&G Ltd?
- Original Post from The Motley Fool Sg


Healthcare companies are generally considered “defensive” stocks since their services are needed in both the good and the bad times. Given their defensive nature and the current fears in the market about a recession, it is not surprising to see that investors are attracted to these stocks.


For those who are seeking investment ideas in this sector, you might want to know which companies you should invest in. In this article, I’ll compare two companies that have exposure to this sector, namely Raffles Medical Group Ltd (SGX: BSL) and Singapore O&G Ltd. (SGX: 1D8).


What I want to find out here is which of the two is the better deal now for investors.


Valuation


To find out which is cheaper, I’ll compare the valuation metrics of both companies. The three valuation metrics I will focus on are the price-to-book (PB) ratio, price-to-earnings (PE) ratio, and dividend yield.


To begin with, Raffles Medical and Singapore O&G have PB ratios of 2.2 and 3.8, respectively. The low PB ratio for Raffles Medical suggests that it has a lower valuation.


Next, Raffles Medical and Singapore O&G have PE ratios of 26.1 and 22.8, respectively. Here, Singapore O&G appears to have a lower valuation.


Last but not least, the dividend yields for Raffles Medical and Singapore O&G are 2.6% and 4.2%, respectively. The higher a stock’s yield, the lower its valuation. Thus, we can see that Singapore O&G has the lower valuation in terms of the dividend yield.


From the above, we can argue that Singapore O&G is probably the cheaper stock among the two due to its low PE ratio and high dividend yield.


Conclusion


For investors, the main takeaway is that Singapore O&G is probably the better deal now due to its low valuation. Yet, investors should also consider the prospects of both companies before investing in their stocks.


Want to start investing but worried about costly mistakes? Our “Heartland Investor” e-book reveals the 1 thing you should NEVER do in the stock market…including ways to handle market crashes. Download the e-book for FREE right here


More reading



The information provided is for general information purposes only and is not intended to be personalised investment or financial advice. Motley Fool Singapore contributor Lawrence Nga doesn’t own shares in any companies mentioned. The Motley Fool Singapore has recommended the shares of Raffles Medical Holdings Ltd and Singapore O&G Ltd.



$Raffles Medical(BSL.SI)

Read more
About Contact Privacy Terms Widgets Store

There are more for you ...

View more and participate in our discussion now. It's FREE.

Creating an account means you’re okay with InvestingNote's Terms and Conditions